Reprogramming Differentiation of NUT Midline Carcinoma by Epigenomic

NUT midline carcinoma (NMC) is a lethal pediatric tumor defined by the presence of BRD-NUT fusion proteins that arrest differentiation. Here we explore the mechanisms underlying the ability of BRD4-NUT to prevent squamous differentiation. In both gain-of and loss-of-expression assays, we find that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression. Bulk chromatin acetylation can be restored by treatment of NMC cells with histone deacetylase inhibitors (HDACi), engaging a program of squamous differentiation and arrested growth in vitro that closely mimics the effects of siRNA-mediated attenuation of BRD4-NUT expression. The potential therapeutic utility of HDACi differentiation therapy was established in three different NMC xenograft models, where it produced significant growth inhibition and a survival benefit. Based on these results and translational studies performed with patientderived primary tumor cells, a child with NMC was treated with the FDA-approved HDAC inhibitor, vorinostat. An objective response was obtained after five weeks of therapy, as determined by positron emission tomography. These findings provide preclinical support for trials of HDACi in patients with NMC. Cancer Res; 71(7); 2686–96.

[1]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[2]  H. Kimura,et al.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains , 2010, The EMBO journal.

[3]  Soo-Youl Kim,et al.  Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[4]  G. Kao,et al.  The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer , 2009, Molecular Cancer Therapeutics.

[5]  M. Rubin,et al.  Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody , 2009, The American journal of surgical pathology.

[6]  Tina N. Davis,et al.  In Vivo Pharmacodynamic Imaging of Proteasome Inhibition , 2009, Molecular imaging.

[7]  Jiong Hu,et al.  Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia , 2009, Proceedings of the National Academy of Sciences.

[8]  C. French.  Demystified molecular pathology of NUT midline carcinomas , 2008, Journal of Clinical Pathology.

[9]  K. Ozato,et al.  The Bromodomain Protein Brd4 Stimulates G1 Gene Transcription and Promotes Progression to S Phase* , 2008, Journal of Biological Chemistry.

[10]  J. Aster,et al.  BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.

[11]  R. Weinberg,et al.  Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. , 2007, Cancer Cell.

[12]  H. Zoghbi,et al.  Glutamine-Expanded Ataxin-7 Alters TFTC/STAGA Recruitment and Chromatin Structure Leading to Photoreceptor Dysfunction , 2006, PLoS biology.

[13]  J. Miyazaki,et al.  Brd4 is required for recovery from antimicrotubule drug-induced mitotic arrest: preservation of acetylated chromatin. , 2005, Molecular biology of the cell.

[14]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[15]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[16]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[17]  C. Antonescu,et al.  Midline carcinoma of children and young adults with NUT rearrangement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. L. Hill,et al.  Translocation (11;15;19): a Highly Specific Chromosome Rearrangement Associated With Poorly Differentiated Thymic Carcinoma in Young Patients , 2003, American journal of clinical oncology.

[19]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[20]  J. Fletcher,et al.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. , 2003, Cancer research.

[21]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[22]  K. Fischbeck,et al.  Histone deacetylase inhibitors reduce polyglutamine toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. D. Dal Cin,et al.  BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). , 2001, The American journal of pathology.

[24]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[25]  L. Mahadevan,et al.  Acetyllysine-binding and function of bromodomain-containing proteins in chromatin. , 2001, Frontiers in bioscience : a journal and virtual library.

[26]  J. Lippincott-Schwartz,et al.  A Bromodomain Protein, MCAP, Associates with Mitotic Chromosomes and Affects G2-to-M Transition , 2000, Molecular and Cellular Biology.

[27]  K. Fischbeck,et al.  CREB-binding protein sequestration by expanded polyglutamine. , 2000, Human molecular genetics.

[28]  Johnson M Liu,et al.  Chromatin remodeling and leukemia: new therapeutic paradigms. , 1999, Blood.

[29]  B. Cheson,et al.  Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. , 1998, Leukemia research.

[30]  S. Corey,et al.  Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid , 1997, Leukemia.

[31]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[32]  E. Middleton,et al.  Differential inhibition of proliferation of human squamous cell carcinoma, gliosarcoma and embryonic fibroblast‐like lung cells in culture by plant flavonoids , 1992, Anti-cancer drugs.

[33]  J. Broach,et al.  Recombination within the yeast plasmid 2μ circle is site-specific , 1982, Cell.

[34]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[35]  Raymond E. Moellering,et al.  Direct inhibition of the NOTCH transcription factor complex , 2010, Nature.

[36]  R. Seethala.  NUT Rearrangement in Undifferentiated Carcinomas of the Upper Aerodigestive Tract , 2009 .

[37]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[38]  K. Chansung,et al.  Complete Remission after Treatment of Acute Promuelocytic Leukemia with Arsenic Trioxide , 1999 .

[39]  N. Speck,et al.  The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. , 1998, Molecular and cellular biology.

[40]  葛目 哲也.  Establishment and characterization of a thymic carcinoma cell line (Ty-82) carrying t(15;19)(q15;p13) chromosome abnormality , 1993 .

[41]  U. Kees,et al.  Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). , 1991, The American journal of pediatric hematology/oncology.